Drugs / Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells
Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05774509 | May 2023 → Jul 2026 overdue | symptomatic heart failure | Assistance Publique - Hôpitaux de Paris | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05774509 ↗ |
| Modality | Other / unclassified | “This work represents a major advance for the use of CPC derived EV-enriched secretomes as a biological drug for cardiac clinical applications.” PMID 40831309 ↗ Aug 2025 |
| Route | Intravenous | “Repeated (X3) intravenous infusions of the extracellular vesicle-enriched secretome of cardiovascular progenitor cells (differentiated from human induced pluripotent stem cells)” NCT05774509 ↗ |